Inventisbio Co. Ltd. and Inventisbio LLC have disclosed new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a signal transducer and activator of transcription 6 (STAT6)-targeting moiety potentially useful for the treatment of cancer.
ATR is a key mediator of the cellular response to replication stress, helping maintain genome integrity during DNA replication. Inhibiting ATR compromises these protective mechanisms, creating a therapeutic vulnerability that is particularly pronounced in ATM-deficient tumors. Researchers at the Hefei Institute of Pharmaceutical Industry reported the identification of a novel series of proteolysis targeting chimeras (PROTACs) designed to induce ATR degradation.
Recurium IP Holdings LLC has disclosed new Wee1-like protein kinase (Wee1) inhibitors and/or degradation inducers potentially useful for the treatment of cancer.
